Katerina Nezvalova-Henriksen

Dr. Katerina Nezvalova-Henriksen

Oslo University Hospital, Rikshospitalet, Oslo, Norway

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2013 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
KNKaterina Nezvalova-Henriksen
Katerina Nezvalova-Henriksen
OSO Spigset
O Spigset
HNH Nordeng
H Nordeng
Objective: To investigate the individual effects of ibuprofen, diclofenac, naproxen, and piroxicam on pregnancy outcome.Design: Cohort study.Setting: Norwegian population.Population: A total of 90 417 women and singleton child pairs.Methods: The Norwegian Mother and Child Cohort Study and Medical Birth Registry of Norway data sets were used.Main outcome measures: Infant survival, congenitalmalformations, structural heart defects, neonatal complications, haemorrhage during pregnancy and postpartum, asthma at age of 18 months.Results: One or more of the four nonsteroidal anti‐inflammatory drugs (NSAIDs) were used by 6511 pregnant women (7.2%). No effect on rates of infant survival, congenital malformation, or structural heart defects was found. The use of ibuprofen in the second trimester was significantly associated with low birthweight (adjusted OR 1.7, 95% CI 1.3–2.3), and ibuprofen use in the second and third trimesters was significantly associated with asthma in 18–month—old children (adjusted OR 1.5, 95% CI 1.2–1.9; adjusted OR 1.5, 95% CI 1.1–2.1). The use of diclofenac in the second trimester was significantly associated with low birthweight (adjusted OR 3.1, 95% CI 1.1–9.0), whereas diclofenac use in the third trimester was significantly associated with maternal vaginal bleeding (adjusted OR 1.8, 95% CI 1.1–3.0). No associations with other neonatal complications were found.Conclusions: The lack of associations with congenital malformations is reassuring. The significant association between diclofenac and ibuprofen use late in pregnancy, and maternal bleeding and asthma in the child, respectively, is consistent with their pharmacological effects. The increased risk of low birthweight may partly have been caused by underlying inflammatory conditions, and was reassuringly similar to the expected baseline risk of low birthweight.

9 June 2011 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
KNKaterina Nezvalova-Henriksen
Katerina Nezvalova-Henriksen
OSOlav Spigset
Olav Spigset
HNHedvig Nordeng
Hedvig Nordeng
Background Guidelines on codeine safety during pregnancy rely on small studies with inconsistent results, and associations between codeine use during pregnancy and increased risk of congenital malformations remain unsubstantiated. Objectives Our objective was to analyze the effect of codeine on pregnancy outcome. Methods Pregnancy outcomes of 2,666 women who used codeine during pregnancy were compared with 65,316 women who used no opioids during pregnancy. Information on maternal sociodemographic and medical characteristics, potential confounders, and pregnancy outcome was obtained from The Norwegian Mother and Child Cohort Study [den norske Mor & barn-undersøkelsen (MoBa)] data set and the Medical Birth Registry of Norway (MBRN) data set. The data sets were linked via the maternal personal identification number. Associations between codeine therapy and pregnancy outcomes were identified using logistic regression analyses. Results No significant differences were found in the survival rate [adjusted odds ratio (OR) 0.9, 95% confidence interval (CI) 0.6–1.5] or the congenital malformation rate (adjusted OR 0.9, 95% CI 0.8–1.1) between codeine-exposed and unexposed infants. Codeine use anytime during pregnancy was associated with planned Cesarean delivery (adjusted OR 1.4, 95% CI 1.2–1.7; P < 0.0001). Third-trimester use was associated with acute Cesarean delivery (adjusted OR 1.5, 95% CI 1.3–1.8; P < 0.0001) and postpartum hemorrhage (adjusted OR 1.3, 95% CI 1.1–1.5; P < 0.0001). No significant associations with other adverse pregnancy outcomes were found. Conclusions No effects of maternal codeine intake during pregnancy were observed on infant survival or congenital malformation rate. Our findings are reassuring; however, the association with acute Cesarean delivery and postpartum hemorrhage may justify a certain level of caution when administering codeine toward the end of pregnancy.

13 April 2010 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
KNKaterina Nezvalova-Henriksen
Katerina Nezvalova-Henriksen
OSOlav Spigset
Olav Spigset
HNHedvig Nordeng
Hedvig Nordeng

17 March 2015 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
SASiri Amundsen
Siri Amundsen
HNHedvig Nordeng
Hedvig Nordeng
KNKaterina Nezvalova-Henriksen
Katerina Nezvalova-Henriksen
LSLars Jacob Stovner
Lars Jacob Stovner
OSOlav Spigset
Olav Spigset

25 July 2013 in European Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
KNKaterina Nezvalova-Henriksen
Katerina Nezvalova-Henriksen
OSOlav Spigset
Olav Spigset
HNHedvig Nordeng
Hedvig Nordeng

1 December 2009 in Cephalalgia
Verified
Journal Article
Open access
KNKaterina Nezvalova-Henriksen
Katerina Nezvalova-Henriksen
OSO Spigset
O Spigset
HNH Nordeng
H Nordeng
Little is known about factors associated with migraine pharmacotherapy during pregnancy. Of 60 435 pregnant women in a population-based cohort, 3480 (5.8%) reported having migraine during the first 5 months of pregnancy. Of these, 2525 (72.6%) reported using migraine pharmacotherapy, mostly non-narcotic analgesics (54.1%) and triptans (25.4%). After adjustment for sociodemographic factors and comorbidities in logistic regression analysis, high pregestational body mass index [odds ratio (OR) 1.3, 95% confidence interval (CI) 1.2, 1.4], sleep < 5 h (OR 1.6, 95% CI 1.3, 1.9), being on sick-leave (OR 1.3, 95% CI 1.2, 1.5) and acute back/shoulder/neck pain (OR 0.6, 95% CI 0.6, 0.7) were associated with migraine pharmacotherapy during pregnancy. Many women need drug treatment for migraine during pregnancy, and the choice of pharmacotherapy during this period may be influenced by maternal sociodemographic factors and comorbidities.